-transparent.png){kind=logo}
Angiotensin II (Ang II) progresses to remodeling of the cardiovascular system through nonhemodynamic as well as hemodynamic effects. There have been few data in vivo on whether subpressor concentration of Ang II is exerted to injure directly the cardiovascular system in hypertension. To test this hypothesis, we investigated, using Dahl salt-sensitive (Dahl S) rats, whether subpressor dose of Ang II progresses to cardiovascular injury observed in salt-induced hypertension. Recent studies have provided evidence that renin-angiotensin inhibition protects against renovascular injury in human hypertension as well as in experimental animals. Particularly in the case of Dahl salt-sensitive rats, a genetic model of volume-dependent hypertension in humans, they are likely to develop more severe arterial and renal injuries than those seen in spontaneously hypertensive rats with similar blood pressure levels. The mechanism of the susceptibility to hypertensive injuries is uncertain; however, renin-angiotensin inhibition significantly improved morphologic and functional injuries in the kidney of Dahl S rats. Conversely, subpressor dose of Ang II infusion exacerbated renal function and progressed to glomerulosclerotic lesions. Alterations of Ang II concentration in physiologic range influenced morphologic and functional injuries in Dahl S rats. Multivariate analysis revealed that activity of the renin-angiotensin system is an independent risk factor to glomerular injury in salt-induced hypertension. These data are in favor of the therapeutic strategy in human hypertension that inhibition of renin-angiotensin system is of value to produce beneficial effects of blood pressure reduction on organ injuries.
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
April 2009,
Journal of hypertension,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
January 2001,
Journal of hypertension,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
November 1999,
Clinical and experimental pharmacology & physiology,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
July 2022,
Medicine and science in sports and exercise,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
June 1997,
Genes and function,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
January 1999,
Journal of hypertension,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
July 2016,
Journal of the renin-angiotensin-aldosterone system : JRAAS,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
September 1998,
Hypertension research : official journal of the Japanese Society of Hypertension,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
July 2021,
Journal of the American Heart Association,
N Hirawa, and
Y Uehara, and
A Numabe, and
Y Kawabata, and
T Gomi, and
T Ikeda, and
T Ohnishi, and
M Ishii, and
M Omata
October 1993,
Journal of hypertension,
